Remote Patient Monitoring Market to Reach US$ 62.2 Bn by 2031, Growing at 12.5% CAGR, Driven by Hospital-at-Home Expansion: Wissen Research

Wissen Research projects the global remote patient monitoring market to expand from $34.5 billion in 2026 to $62.2 billion by 2031, a 12.5% CAGR, driven by reimbursement support, hospital-at-home adoption and AI-enabled clinical monitoring. Cardiovascular applications and connected devices led the market in 2025; North America remains the largest region while Asia-Pacific is forecast to grow fastest. Growth opportunities are tempered by cybersecurity, interoperability, patient-adherence, alert-fatigue and fraudulent-billing risks, although recent Philips, Abbott and Oracle initiatives highlight continued investment in scalable RPM infrastructure.

Analysis

This is directionally supportive for closed-loop cardiac and diabetes ecosystems, but the revenue capture is uneven. ABT and DXCM monetize recurring consumables and have direct clinical-evidence/reimbursement leverage; IRTC has higher operating leverage to ambulatory cardiac-monitoring volumes but also greater exposure to reimbursement audits and referral concentration. PHG, GEHC and MDT benefit more from enterprise deployments, where multi-year implementation cycles defer revenue recognition and make near-term upside less visible than the market-growth narrative implies.

The non-obvious bottleneck is not device availability but clinical workflow capacity. Platforms that reduce false-positive alerts and integrate into hospital EHRs can win disproportionate share, favoring ORCL's interoperability layer and established acute-care vendors over standalone monitoring software. Conversely, TDOC remains a weak pure-play expression: RPM enrollment can increase virtual-care engagement, but device procurement, staffing and reimbursement administration may sit with providers or hardware partners rather than accrue to TDOC's margin.

Near term, this third-party market forecast is not independently investable and should not move estimates absent provider utilization or reimbursement data. Over 1-3 months, monitor CMS proposed-rule language, OIG enforcement actions, and quarterly disclosures on active monitored patients, sensor utilization and gross margin. Over 6-18 months, tighter billing documentation could consolidate share toward scaled, evidence-backed incumbents while compressing economics for smaller RPM vendors; the thesis is falsified if reimbursement rates decline, hospital-at-home programs fail to demonstrate readmission savings, or cybersecurity/integration costs delay deployments.

Consensus likely overweights AI as a standalone pricing catalyst. In this market, AI raises value only if it lowers nursing labor per enrolled patient and produces auditable outcomes; otherwise it increases liability and implementation expense. The better trade is recurring sensor and cardiac-monitoring exposure rather than broad digital-health beta.

Key Decisions for Investors

• Initiate a 6-12 month long ABT / short TDOC pair, sized market-neutral: ABT has recurring monitoring consumables and diversified earnings support, while TDOC has less certain RPM revenue capture. Target 15-20% relative return; exit if ABT reports monitoring utilization below plan or TDOC demonstrates sustained RPM-driven EBITDA-margin expansion.
• Accumulate IRTC on reimbursement-related weakness rather than chase momentum, with a 9-12 month horizon. The upside requires volume growth plus operating leverage from fixed clinical infrastructure; cap risk with a stop on a material adverse CMS/OIG billing development or a quarterly reduction in revenue-per-test.
• Maintain an overweight in DXCM versus MDT for 6-18 months where portfolio mandates allow: diabetes monitoring has more consumable pull-through and clearer patient engagement than broad hospital-monitoring capex. Reassess if DXCM's sensor utilization growth decelerates materially or payer access worsens.
• Place an event-driven watch on ORCL and GEHC ahead of healthcare IT bookings disclosures and CMS rulemaking; do not initiate solely on this report. Upgrade to a long only if validated-device integrations translate into contracted backlog or recurring software revenue, rather than unpaid partnership announcements.